drugset
drugset / Trial / NCT00502879

Study Evaluating Etanercept 25mg or 50mg Administered Subcutaneously to Healthy Chinese Male Subjects

NCT00502879 ↗

Phase 1 Completed Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of this study is to assess the pharmacokinetics of etanercept in healthy Chinese male subjects. Safety and tolerability data will also be obtained.

Timeline

Start
2007-07
Primary completion
—
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 25 mg Subcutaneous
Subject Etanercept Protein / enzyme biologic 50 mg Subcutaneous

Indications

No indication recorded.